References
- Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang J-Y, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183–97
- Kang MJ, Jang JY, Lee KB, Chang YR, Kwon W, Kim S-W. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: Implications for postoperative surveillance. Ann Surg 2014;260:356–63
- Passot G, Lebeau R, Hervieu V, Ponchon T, Pilleul F, Adham M. Recurrences after surgical resection of intraductal papillary mucinous neoplasm of the pancreas: A single-center study of recurrence predictive factors. Pancreas 2012;41:137–41
- Thomassen I, Lemmens VEPP, Nienhuijs SW, Luyer MD, Klaver YL, de Hingh IHJT. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: A population-based study. Pancreas 2013;42:72–5
- Yarema RR, Ohorchak MA, Zubarev GP, Mylyan YP, Oliynyk YY, Zubarev MG, et al. Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: Results of a single-centre retrospective study. Int J Hyperthermia 2014;30:159–65
- Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macr A, et al. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cáncer. Eur J Surg Oncol 2011;37:4–9
- Farma JM, Pingpank JF, Libutti SK, Bartlett DL, Ohl S, Beresneva T, et al. Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. J Gastrointest Surg 2005;9:1346–53
- Chua T, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? Ann Surg 2009;249:900–7
- Glehen O, Gilly F, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from non-ovarian origin by cytoreductive surgery combined with perioperative intrapertoneal chemotherapy. Cancer 2010;116:5608–18
- Arjona-Sanchez A, Muñoz-Casares FC, Casado-Adam A, Sanchez-Hidalgo JM, Ayllon Teran MD, Orti-Rodriguez R, et al. Outcome of patients with aggressive pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy. World J Surg 2013;37:1263–70